# Intelligent Bio Solutions Inc.: overview INBS · Nasdaq · CIK 1725430 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/inbs.md) · [Financials](/companies/inbs/financials.md) · [Filings](/companies/inbs/filings.md) · [Insiders](/companies/inbs/insiders.md) Latest reported revenue: [$1.1m](/filings/0001493152-26-039136.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 19, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-039136). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [872](/filings/0001493152-25-021751.md) | [607](/filings/0001493152-26-006311.md) | [729](/filings/0001493152-26-022617.md) | [844 d](/filings/0001493152-26-039136.md) | [1,112](/filings/0001493152-25-021751.md) | [897](/filings/0001493152-26-006311.md) | [1,061](/filings/0001493152-26-022617.md) | [1,146 d](/filings/0001493152-26-039136.md) | | Gross margin | % | [39.8%](/filings/0001493152-25-021751.md) | [36.7%](/filings/0001493152-26-006311.md) | [46.8%](/filings/0001493152-26-022617.md) | [39.8% d](/filings/0001493152-26-039136.md) | [46.6%](/filings/0001493152-25-021751.md) | [51.3%](/filings/0001493152-26-006311.md) | [50.5%](/filings/0001493152-26-022617.md) | [46.8% d](/filings/0001493152-26-039136.md) | | Operating margin | % | [(312.4%)](/filings/0001493152-25-021751.md) | [(372.8%)](/filings/0001493152-26-006311.md) | [(351.3%)](/filings/0001493152-26-022617.md) | [(368.1%) d](/filings/0001493152-26-039136.md) | [(269.8%)](/filings/0001493152-25-021751.md) | [(293.9%)](/filings/0001493152-26-006311.md) | [(277.8%)](/filings/0001493152-26-022617.md) | [(346.4%) d](/filings/0001493152-26-039136.md) | | Net margin | % | [(307.9%)](/filings/0001493152-25-021751.md) | [(370.3%)](/filings/0001493152-26-006311.md) | [(349.0%)](/filings/0001493152-26-022617.md) | [(366.2%) d](/filings/0001493152-26-039136.md) | [(268.3%)](/filings/0001493152-25-021751.md) | [(298.6%)](/filings/0001493152-26-006311.md) | [(269.9%)](/filings/0001493152-26-022617.md) | [(341.0%) d](/filings/0001493152-26-039136.md) | | Diluted EPS | $ per share | [(0.70)](/filings/0001493152-25-021751.md) | [(4.96)](/filings/0001493152-26-006311.md) | [(4.41)](/filings/0001493152-26-022617.md) | not reported | [(0.35)](/filings/0001493152-25-021751.md) | [(2.82)](/filings/0001493152-26-006311.md) | [(1.80)](/filings/0001493152-26-022617.md) | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(2,917)](/filings/0001493152-25-021751.md) | [(1,636) d](/filings/0001493152-26-006311.md) | [(4,343) d](/filings/0001493152-26-022617.md) | [(3,182) d](/filings/0001493152-26-039136.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.4](/filings/0001493152-22-026526.md) | [1.3](/filings/0001493152-24-036953.md) | [3.1](/filings/0001641172-25-024279.md) | [3.1](/filings/0001493152-26-039136.md) | [4.2](/filings/0001493152-26-039136.md) | | Gross margin | % | not reported | [26.0%](/filings/0001493152-24-036953.md) | [45.8%](/filings/0001641172-25-024279.md) | [40.8%](/filings/0001493152-26-039136.md) | [48.6%](/filings/0001493152-26-039136.md) | | Operating margin | % | [(1907.1%)](/filings/0001493152-23-029992.md) | [(1002.1%)](/filings/0001493152-24-036953.md) | [(330.5%)](/filings/0001641172-25-024279.md) | [(349.8%)](/filings/0001493152-26-039136.md) | [(299.1%)](/filings/0001493152-26-039136.md) | | Net margin | % | [(1900.1%)](/filings/0001493152-23-029992.md) | [(845.9%)](/filings/0001493152-24-036953.md) | [(326.4%)](/filings/0001641172-25-024279.md) | [(346.2%)](/filings/0001493152-26-039136.md) | [(294.9%)](/filings/0001493152-26-039136.md) | | Diluted EPS | $ per share | [(11.33)](/filings/0001493152-23-029992.md) | [(127.00)](/filings/0001493152-24-036953.md) | [(6.38)](/filings/0001641172-25-024279.md) | [(20.04)](/filings/0001493152-26-039136.md) | [(8.44)](/filings/0001493152-26-039136.md) | | Free cash flow | $m | not reported | not reported | [(9.8)](/filings/0001641172-25-024279.md) | [(9.9)](/filings/0001493152-26-039136.md) | [(12.1)](/filings/0001493152-26-039136.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inbs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $324.5k | 141,397 | | Added +11,397 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $47.8k | 20,840 | | Reduced −7,769 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.3k | 5,810 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $13.2k | 5,735 | | Added +5,363 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $9.1k | 3,958 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $7.5k | 3,280 | | Added +2,030 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $460 | 200 | | Unchanged | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $326 | 142 | | New +142 | ## Recent filings [All 465 filings](/companies/inbs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 21:00 ET | [10-K/A](/filings/0001493152-26-047925.md) | Annual report, amended, period 2026-06-30 | 0001493152-26-047925 | | 2026-10-13 | 21:00 ET | [8-K](/filings/0001493152-26-046863.md) | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-046863 | | 2026-09-11 | 21:00 ET | [8-K](/filings/0001493152-26-042411.md) | 8.01 Other events | 0001493152-26-042411 | | 2026-09-09 | 12:50 ET | [8-K](/filings/0001493152-26-041901.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-041901 | | 2026-09-02 | 21:00 ET | [8-K](/filings/0001493152-26-041253.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041253 | | 2026-09-01 | 21:10 ET | [8-K](/filings/0001493152-26-041055.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041055 | | 2026-08-28 | 21:20 ET | [8-K](/filings/0001493152-26-040656.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-040656 | | 2026-08-19 | 12:50 ET | [8-K](/filings/0001493152-26-039140.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-039140 | | 2026-08-19 | 12:30 ET | [10-K](/filings/0001493152-26-039136.md) | Annual report, period 2026-06-30 | 0001493152-26-039136 | | 2026-08-11 | 21:29 ET | [8-K](/filings/0001493152-26-037206.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037206 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001493152-26-039136.md), filed Aug 19, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5072f12a-7dd1-4778-bd82-f604eced133b) ## About the filer - CIK: 1725430 - Tickers: INBS - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.